Show simple item record

dc.contributor.authorXiang, Y
dc.contributor.authorHuang, G
dc.contributor.authorShan, Z
dc.contributor.authorPan, L
dc.contributor.authorLuo, S
dc.contributor.authorYang, L
dc.contributor.authorShi, L
dc.contributor.authorLi, Q
dc.contributor.authorLeslie, RD
dc.contributor.authorZhou, Z
dc.date.accessioned2021-03-24T11:05:59Z
dc.date.available2015-07-17
dc.date.available2021-03-24T11:05:59Z
dc.date.issued2015-12
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/70838
dc.description.abstractAIMS: Adult-onset autoimmune diabetes is prevalent in China, in contrast to childhood-onset type 1 diabetes mellitus. Islet autoantibodies are the most important immune biomarkers to diagnose autoimmune diabetes. We assayed four different islet autoantibodies in recently diagnosed adult non-insulin-requiring diabetes Chinese subjects to investigate the best antibody assay strategy for the correct diagnosis of these subjects. METHODS: LADA China study is a nation-wide multicenter study conducted in diabetes patients from 46 university-affiliated hospitals in China. Non-insulin-treated newly diagnosed adult diabetes patients (n = 2388) were centrally assayed for glutamic acid decarboxylase autoantibody (GADA), protein tyrosine phosphatase-2 autoantibody (IA-2A), and zinc transporter 8 autoantibody (ZnT8A) by radioligand assay and insulin autoantibody (IAA) by microtiter plate radioimmunoassay. Clinical data were determined locally. RESULTS: Two hundred and six (8.63 %) subjects were autoantibody positive, of which GADA identified 5.78 % (138/2388) of the total, but only 67 % (138/206) of the autoimmune cases. IA-2A, ZnT8A, and IAA were found in 1.51, 1.84, and 1.26 % of the total study subjects, respectively. When assaying three islet autoantibodies, the most effective strategy was the combination of GADA, ZnT8A, and IAA, which could identify 92.2 % (190/206) autoimmune diabetes patients. The clinical data showed that those subjects with positive GADA had lower random C-peptide than autoantibody negative subjects (P < 0.05). CONCLUSIONS: As with Europeans, GADA is the dominant autoantibody in this form of autoimmune diabetes in China, but in contrast to Europeans, screening should include other diabetes-associated autoantibodies.en_US
dc.format.extent1121 - 1127
dc.languageeng
dc.relation.ispartofActa Diabetol
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectGlutamic acid decarboxylase antibody (GADA)en_US
dc.subjectInsulin autoantibody (IAA)en_US
dc.subjectLatent autoimmune diabetes of adults (LADA)en_US
dc.subjectProtein tyrosine phosphatase-2 antibody (IA-2A)en_US
dc.subjectZinc transporter 8 autoantibody (ZnT8A)en_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAsian Continental Ancestry Groupen_US
dc.subjectAutoantibodiesen_US
dc.subjectBiomarkersen_US
dc.subjectCation Transport Proteinsen_US
dc.subjectChinaen_US
dc.subjectDiabetes Mellitus, Type 2en_US
dc.subjectFemaleen_US
dc.subjectGlutamate Decarboxylaseen_US
dc.subjectHumansen_US
dc.subjectIslets of Langerhansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectPrevalenceen_US
dc.subjectProtein Phosphatase 2en_US
dc.subjectZinc Transporter 8en_US
dc.titleGlutamic acid decarboxylase autoantibodies are dominant but insufficient to identify most Chinese with adult-onset non-insulin requiring autoimmune diabetes: LADA China study 5.en_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s00592-015-0799-8
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/26239144en_US
pubs.issue6en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume52en_US
dcterms.dateAccepted2015-07-17


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States